Abarca Health

Medicare Drug Negotiation Is the Model for the Future of Drug Pricing, Abarca CEO Says

For the first time ever, CMS is preparing to negotiate prices for drugs paid for by Medicare. This has sparked a huge debate — will the creation of this taxpayer-funded drug negotiation infrastructure be a failed experiment, or will it become the standard for the future of drug pricing in this country? Jason Borschow, president and CEO of Abarca Health, says it's the latter.

By Katie Adams

BioPharma, Payers

Outcome-based contracts likely to keep growing, evolving despite challenges

Although they've seen growth in the last few years, full implementation of outcome-based contracts faces hurdles like expensive technology, outmoded infrastructure and regulations that get in the way.

By Alaric DeArment

The Funding Model for Cancer Innovation is Broken — We Can Fix It

Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.

By Eve McDavid - CEO of Mission-Driven Tech